Acute Myeloid Leukaemia
Conditions
Interventions
investigational material(s)
Generic name etc : AZD1152
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material
Sponsors
AstraZeneca
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Ages Eligible for Study: 20 Years and older Genders Eligible for Study: Both Inclusion Criteria: - Subjects must be in first, second or third relapse at least one month after completion of initial course of induction and consolidation therapy (may include autologous transplant but not allogenic stem cell transplantation) - Newly diagnosed Acute Myeloid Luekimia who are not considered suitable for other treatments. Exclusion Criteria: - Previous myeloablative therapy with autologous or allogenic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose. - Participation in any other trial with an investigational product within the previous 30 days. - Other active malignancy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety Primary Outcome Measures: - To assess the safety and tolerability of AZD1152 in patients with AML by assessment of AEs, vital signs, ECG parameters, clinical chemistry, haematology (including clotting parameters) and urinalysis Secondary Outcome Measures: - To examine the pharmacokinetics of AZD1152 | — |
Outcome results
None listed